A Switchable Bispecific T-Cell Nanoengager (sBiTNE) to link T cells with cancer cells that can be reversed if off-tumor toxicity is detected.
A method to inhibit small extracellular vesicles (sEVs) released by tumor cells to enhance lipid nanoparticle (LNP) accumulation in tumors.
Ionizable LNPs with a rigid backbone of piperazine (PIP) linked to bisphosphonates (BPs) for the targeted delivery of mRNA to the bone.
A method to streamline the process of generating chimeric antigen receptor (CAR) T cells for therapeutic applications.
[%brief%]
CAR-T cells are PEGylated to block the interactions with monocytes and macrophages to reduce the side effects of CAR-T cell therapies (cytokine release syndrome and neurotoxicity).
Peptide-functionalized lipid nanoparticles (pLNPs) for targeted messenger RNA (mRNA) delivery to the brain.
Lung-targeting lipid nanoparticles allowing organ specific mRNA delivery for gene therapy applications.
Using Mannich reaction-based combinatorial libraries to identify ionizable lipids for low-immunogenic and high-efficiency mRNA delivery.
Using mRNA-LNPs to deliver forkhead box protein 3 (Foxp3) to CD4+ T cells to engineer Foxp3-positive T (FP3T) cells with immunosuppressive properties.